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Abstract: Estrogens have been recognized as a major regulator of
vascular tone and structure, particularly in the skin. The objective of
this study was to investigate the effects of endogenous estrogens on
the skin microcirculation. Skin blood flow was measured at the
forearm at rest and during postischemic hyperemia using laser
Doppler flowmetry in 32 healthy women (mean age 34.56 3.9 years)
involved in an in-vitro fertilization program. Women were treated for
10 to 12 days with gonadotropin-releasing hormone agonist (total
dose 40.3 6 3.3 mg) and human menopausal gonadotropin (1942 6
801 IE) or follicle-stimulating hormone (2544 6 1071 IE) according
to individual estrogen levels. Plasma estrogen levels increased from
1326 90 pmol/L (366 25 pg/mL) to 84716 4386 pmol/L (23086
1195 pg/mL) during treatment (P , 0.0001). Maximal hyperemic
blood flow increased from 353 6 81% before treatment to 516 6
144% after hormonal stimulation (P , 0.0001), whereas basal skin
flow was not altered. This study shows that endogenous estrogens
enhance the postischemic hyperemic response of the skin microcir-
culation.
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Estrogens exert profound and broad actions on thevasculature. Indeed, clinical observation of the skin before
and after menopause as well as during pregnancy suggest an
important role of female sex hormones for skin perfusion and
metabolism. In the coronary circulation, estrogen acts as
a vasodilator.1 Estrogens modulate the production of endo-
thelium-derived vasoactive substances, eg, nitric oxide (NO)2
and endothelin-1 (ET-1), and thus influence vascular tone and
structure.3 Estrogens also influence the actions of ET-1 at the
ETB receptor level.
4 NO causes vasodilatation, inhibits platelet
aggregation, suppresses smooth-muscle cell proliferation, and
acts as an antiatherogenic factor.5 ET-1 opposes the effects of
NO, causes potent vasoconstriction of the systemic and pulmo-
nary vasculature, promotes monocyte adhesion to the vascular
wall, activates macrophages, and promotes vascular smooth-
muscle cell proliferation. Continuous release of NO and ET-1
from the endothelium influences basal vascular tone.6,7
We have previously demonstrated that postischemic hy-
peremia in the skin microcirculation is dependent on vasodi-
lator prostaglandins.8 The precise effects of endogenous estrogens
on the microcirculation still remain elusive. The aim of this
study, therefore, was to investigate the impact of endogenous
estrogens on the skin microcirculation during stimulation of
endogenous estrogen production in healthy women.
MATERIALS AND METHODS
Study Population
Thirty-two women with an average age of 34 6 3.9
years were studied during an in-vitro fertilization program. To
be considered eligible for the study women had to be in
reproductive period, with regular menstrual cycles of between
26 and 32 days during the last 6 months. Exclusion criteria
were clinical or laboratory evidence of endocrine disease;
a history of renal, respiratory, hematological, neurologic, or
gastrointestinal disease; clinically significant ophthalmic
abnormalities; malignancy; or chronic alcohol or drug abuse.
As control group, 7 women not showing the expected increase
in estrogen levels were studied. These women were considered
nonresponders to stimulation therapy as they were not showing
the expected.50-fold increase in estradiol levels. The control
group was studied in parallel fashion under the same
conditions to account for possible confounding factors.
Protocol
Women were treated for 10 to 12 days with gonado-
tropin-releasing hormone-agonist (GnRHa) with an average
total dose of 40.3 6 3.3 mg. They were additionally treated
with human menopausal gonadotropin (HMG, average total
dose 1942 6 801 IE), or follicle stimulating hormone (FSH,
average total dose 25446 1071 IE). The dosing of FSH/HMG
was chosen according to individual estrogen levels.
Measurement of Skin Reactive Hyperemia
A laser Doppler flowmeter (PF3, Perimed, Sweden) with
a probe holder was used to assess skin blood flow as previously
described.8 The laser probe was placed on the forearm distal
from a blood pressure cuff loosely placed around the upper
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arm. Stable baseline conditions were recorded for 2 minutes.
Then, the cuff was inflated to suprasystolic pressure for 4.5
minutes. After release of the cuff, skin reactive hyperemia was
recorded. The measurement of skin blood flow is different
from techniques for assessment of whole forearm blood flow
such as venous occlusion plethysmography in that it
specifically measures skin vessels. In contrast to ultrasonog-
raphy of large arteries, conduit vessel function is not assessed
by laser Doppler flowmetry of the skin.
All patients were studied under standardized conditions,
ie, in the morning (8:00 AM) in a temperature-controlled room
(23C). Subjects abstained from smoking for 24 hours, from
caffeine- and alcohol-containing beverages for 12 hours, and
from food for 2 hours before the test. Blood pressure was
measured with appropriate cuff size after the patient had been
supine for at least 15 minutes.
Biochemical Analyses
Blood samples were taken before treatment and after
5, 8, and 10 to 12 days of treatment. Serum levels of 17b-
estradiol and progesterone were measured by radioimmuno-
assay. Levels are reported as picomoles/liter as well as
picograms/milliliter (to convert, divide by 3.671).
Statistical Analysis
Basal skin blood flow, peak skin blood flow, and half-life
of the hyperemic response were calculated (Matlab, Math
Works, Natick, MA). Results represent arbitrary flow units.
Maximal blood flow was normalized to resting blood flow and
expressed as percentage increase.
Values represent means 6 SEM. Single comparisons
were made with paired and unpaired Student t test. Effects of
treatment were compared using ANOVA for repeated
measurements (StatView 4.5, Abacus Concepts, Berkeley,
CA). A P value of 0.05 or less was considered statistically
significant.
RESULTS
The clinical characteristics of the study participants are
shown in Table 1. During the in-vitro fertilization program,
17b-estradiol plasma levels significantly increased (Table 1).
There was an accompanying significant increase in blood
pressure and body weight.
Basal skin blood flow did not change during the study
course (Table 2). Hyperemic blood flow after cuff deflation
increased from 353 6 81% to 516 6 144% of baseline blood
flow (P , 0.0001, Table 2 and Fig. 1). Body temperature was
comparable before and after therapy (36.5 6 0.4 and 36.8 6
0.6C, ns).
In the control group consisting of women only poorly
responding to stimulation with an increase in 17b-estradiol
levels (from 75 6 63 to 967 6 823 pmol/L, P = 0.0007; ie,
20 6 17 to 263 6 224 pg/mL), the increase in maximal
postischemic blood flow was blunted (from 411 6 155% to
438 6 171%, P = 0.068).
DISCUSSION
The present study demonstrates for the first time that
endogenous estrogens have a profound influence on the regu-
lation of blood flow in the skin microcirculation. The increase
in estrogen levels after hormone therapy was associated with
enhanced postischemic skin blood flow, although there was no
change in basal skin perfusion.
Reactive hyperemia of the skin bases is determined by
a complex interplay of several vasoactive substances including
NO, prostaglandins, adenosine, ATP-sensitive potassium chan-
nels, and oxygen. We have previously demonstrated that
postischemic hyperemia of the skin is mainly dependent on
vasodilator prostaglandins.8 This is in contrast to large pe-
ripheral conduit arteries where nitric oxide (NO) is mainly
TABLE 1. Clinical Parameters During the Study Course
17ß-estradiol
(pmol/L)
SBP
(mm Hg)
DBP
(mm Hg)
HR
(bpm)
BMI
(kg/m2)
Day 1 132 6 90 109 6 11 72 6 6 76 6 11.6 24.8 6 3.5
Day 5 2290 6 1002 112 6 9 73 6 7 76 6 10.5 25.5 6 3.6
Day 8 5144 6 2365 118 6 11 75 6 6 76 6 11.6 25.6 6 3.6
Day 10 8471 6 4386* 123 6 9* 78 6 5† 78 6 10.0 25.8 6 3.5*
DPB denotes diastolic blood preassure; SBP, systolic blood pressure; HR, heart rate;
BMI, body mass index. To convert estradiol levels from pmol/L to pg/mL, divide by
3.671.
*P # 0.0001, †P = 0.0024 by ANOVA.
TABLE 2. Changes in Skin Blood Flow During
Estrogen-Stimulating Therapy
Basal Skin
Blood Flow
(Units)
Maximal
Postischemic
Blood Flow (Units)
Half-Life of
Hyperemic Response
(Seconds)
Day 1 15.6 6 4.8 65 6 20 43 6 18
Day 5 14.6 6 4.0 73 6 24 39 6 17
Day 8 14.7 6 5.1 80 6 28 39 6 13
Day 10 13.7 6 3.2 88 6 27* 32 6 11
*P , 0.0001 by ANOVA.
FIGURE 1. Reactive hyperemia in the skin before and after 10
days of estrogen stimulation in healthy women. Stimulation of
endogenous estrogen release led to an increase in post-
ischemic reactive hyperemia of the skin (*P , 0.0001). Basal
skin blood flow did not change during the study course.
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responsible for flow-mediated vasodilation.9 Postischemic skin
hyperemia is impaired in hypercholesterolemic patients and
can be enhanced by cholesterol-lowering therapy.8,10 Because
laser Doppler flowmetry is a simple noninvasive method for
measuring skin blood flow during reactive hyperemia, it can be
used clinically to test and monitor vascular function during
physiological or therapeutic interventions.8
The present study shows that in healthy women of
gestational age without cardiovascular risk factors, estrogens
have profound impact on microvascular function. Postische-
mic skin reactive hyperemia considerably increased in these
women participating in an in vitro fertilization program
resulting in pronouned estrogen stimulation (about 60-fold
increase in estradiol levels). In the control group consisting of
women who showed only a moderate increase in estrogen
levels (about 12-fold), the increase in postischemic blood flow
was blunted. In untreated women not undergoing estrogen
stimulation, estradiol levels typically increase 10-fold at the
time of ovulation with large interindividual variation.
Estrogens exert both rapid and long-term effects on the
endothelium and are involved in the flow-mediated and shear
stress–induced release of vasoactive substances.3 On the basis
of our and others’ previous work investigating the mechanisms
involved in postischemic reactive hyperemia of the skin,8,11 an
enhancement of vasodilator prostaglandins may be responsible
for the improvement of reactive hyperemia induced by increased
estrogen levels in the present study. These mechanisms are
different from those in flow-induced dilatation of large pe-
ripheral and coronary arteries.9 However, impaired endothelial
function in postmenopausal women is improved by hormone
replacement.12
Interestingly, basal skin perfusion was not altered by
estrogen stimulation, although alterations in skin perfusion
occur during a normal menstrual cycle.13,14 Basal skin per-
fusion is largely influenced by NO.15 These findings delineate
the differences in the regulation of the skin and muscle micro-
circulation. NO is an important regulator of basal blood flow in
the skeletal and myocardial microcirculation. Because hor-
mone replacement therapy does not affect basal or stimulated
skin blood flow in postmenopausal women,16 the question arises
whether endogenous and exogenous estrogens have pro-
foundly different effects on the circulatory regulation. The dis-
appointing results from hormone replacement therapy trials in
postmenopausal women with coronary artery disease support
this view. Although myocardial ischemia in women with stable
angina is reduced by hormone replacement therapy,17 large
clinical trials yielded no benefit in terms of mortality.
Besides of the role of estrogens in the normal aging skin,
the regulation of skin perfusion is of interest in many clinical
conditions. Raynaud phenomenon causes significant symp-
toms in affected patients. Female patients with Raynaud
phenomenon show altered regulation of skin perfusion during
the menstrual cycle.18 As stimulation of endogenous estrogens
leads to a potentiation of postischemic skin blood flow, the
present results are in line with a major role of estrogens in the
regulation of skin perfusion and thermoregulation.19–21 Such
an important regulator function helps to explain alterations
in thermoregulation of the skin in postmenopausal versus
premenopausal women, which is often responsive to estrogen
replacement therapy.21–24 Moreover, the postischemic response
to reperfusion injury depends on estrogen status.25 Delayed
wound healing in the elderly also responds to topical estrogen
administration,26 as inflammatory mechanisms provoke hy-
peremia of the skin, which may be increased by estrogens.
In addition to the observed alterations in skin perfusion,
the increase in 17b-estradiol levels was accompanied by an
increase in systolic and diastolic blood pressure. Also, there
was an increase in body weight. The observed hemodynamic
changes are thus likely caused by estrogen-induced volume
retention. Activation of the renin–angiotensin system may
have contributed.
The present study is limited by the fact that it is not
randomized and placebo-controlled. However, the observed
differences were indeed large; thus, minor and accidental
variations on a daily basis are unlikely to play a role. Another
limiting factor is the regulation of skin blood flow by other
systems than the endothelium, eg, the sympathetic nervous
system. Skin temperature might influence postischemic skin
blood flow. However, this was monitored closely in our study
and cannot explain the improvement of reactive hyperemia.
Performing the experiments in an air-conditioned and quiet
room minimized these confounding influences, eg, noise and
changing temperature, as well.
In conclusion, this study demonstrates that endogenous
estrogens improve postischemic blood flow in the skin micro-
circulation. These results underline the regulatory role of en-
dogenous estrogens in the normal aging skin and in many
clinical conditions with dysregulated cutaneous perfusion.
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